The company is seeking approval for tukysa and trastuzumab combination for the treatment of HER2-positive colorectal cancer in adult patients who have received at least one treatment regimen The post FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine appeared first on Pharmaceutical Business review. … [Read more...]

The collaboration will use the companies’ respective strengths to support the development of ASO-based precision medicine therapies and for creating compelling value opportunities for Vanda and OliPass. It The post Vanda partners with OliPass to develop ASO-based therapeutics appeared first on Pharmaceutical Business review. … [Read more...]

This approval makes Dupixent the first and only medicine available in the US for the treatment of prurigo nodularis, a chronic and debilitating skin disease. A fully human The post US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis appeared first on Pharmaceutical Business review. … [Read more...]

A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells/tumours which harbour deficiency in homologous recombination repair (HRR), The post China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer appeared first on Pharmaceutical Business review. … [Read more...]

As part of the collaboration deal, the companies will use ArsenalBio’s T cells screening and engineering technology for identifying the critical success circuits in T cell-based therapies. Genentech, The post ArsenalBio, Genentech partner to identify T-Cell therapies for cancer appeared first on Pharmaceutical Business review. … [Read more...]